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Abstract
Accruing evidence reveals best practices for how to help individuals living with Sickle Cell
Disease (SCD); yet, the implementation of these evidence-based practices in healthcare
settings is lacking. The Sickle Cell Disease Implementation Consortium (SCDIC) is a
national consortium that uses implementation science to identify and address barriers to
care in SCD. The SCDIC seeks to understand how and why patients become unaffiliated
from care and determine strategies to identify and connect patients to care. A challenge,
however, is the lack of agreed-upon definition for what it means to be unaffiliated and what it
means to be a “SCD expert provider”. In this study, we conducted a Delphi process to obtain
expert consensus on what it means to be an “unaffiliated patient” with SCD and to define an
“SCD specialist,” as no standard definition is available. Twenty-eight SCD experts participated in three rounds of questions. Consensus was defined as 80% or more of respondents
agreeing. Experts reached consensus that an individual with SCD who is unaffiliated from
care is “someone who has not been seen by a sickle cell specialist in at least a year.” A
sickle cell specialist was defined as someone with knowledge and experience in SCD. Having “knowledge” means: being knowledgeable of the 2014 NIH Guidelines, “EvidenceBased Management of SCD”, trained in hydroxyurea management and transfusions, trained
on screening for organ damage in SCD, trained in pain management and on SCD emergencies, and is aware of psychosocial and cognitive issues in SCD. Experiences that are
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What is an unaffiliated patient?

expected of a SCD specialist include experience working with SCD patients, mentored by a
SCD specialist, regular attendance at SCD conferences, and obtains continuing medical
education on SCD every 2 years.” The results have strong implications for future research,
practice, and policy related to SCD by helping to lay a foundation for an new area of
research (e.g., to identify subpopulations of unaffiliation and targeted interventions) and policies that support reaffiliation and increase accessibility to quality care.

Introduction
Sickle cell disease (SCD) is an inherited group of blood disorders characterized by an abnormal
form of hemoglobin molecule in red blood cells that transport oxygen throughout the body
[1]. It is a severe and debilitating illness that can substantially affect sufferers’ length and quality of life. Currently, SCD affects an estimated 100,000 individuals living in the United States,
with a shortage of adult-oriented providers trained in SCD to sufficiently meet their needs
[2,3]. As a result, many adults with SCD are not regularly seen by a provider with knowledge
of best clinical practices in SCD; instead, they receive exclusively episodic acute care, often in
the emergency department (ED) [4]. In the absence of any national public health surveillance
tracking system or registry of individuals with SCD, the extent of the problem of lack of comprehensive care by SCD expert physicians is currently unknown. Since the therapeutic scenario is evolving with new treatments regularly available, there is a need for increased
empirical attention on individuals with SCD not affiliated with care.
There is very little information available about the subpopulation of individuals with SCD
without comprehensive care from a research perspective. While some information is known
about certain subpopulations of individuals with SCD not receiving care (e.g., those who
appear in the ED or those that were lost during transition to adult care), the scope of the problem of patients unaffiliated with care has not been systematically examined. Part of this lack of
knowledge is that the term “unaffiliated” has not been well defined for SCD as it has in other
rare diseases. We anticipate that this is a heterogeneous group of individuals, but lack of consensus about definitional terms has prevented forward movement in developing diverse interventions to find and connect different subpopulations of unaffiliated individuals with care.
The purpose of this study was to better define what it means to be unaffiliated from SCD care
and what it means to be an SCD specialist. Using these definitions, we can better design and
quantify the impact of interventions to improve this public health deficit in the future.

The problem Of unaffiliation
Although a relatively rare disease, SCD places a heavy burden on the health care system [5,6].
Approximately $488 million was spent on SCD-related expenditures in the year 2004 alone,
much higher than the general population [5,6]. One driver underlying high costs is the frequency of hospitalizations for SCD-related illnesses [7,8]. Patients with SCD have an estimated
7–30 times higher rates of hospitalization and 2–6 times higher rates of ED usage than the general population [9]. Overreliance on EDs or hospitalization is a concern for both quality and
cost-efficient care of SCD. Proper management of SCD requires evidence-based comprehensive and preventive care in an outpatient setting [10,11] coupled with availability of an infusion
center or ED for management of the acute complications associated with SCD. Because
sequential outpatient preventive care is not designed to be provided within the ED system,
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heavy reliance on ED services over a comprehensive care approach may obstruct optimal clinical outcomes [9,12].
In 2014, guidelines for the care of SCD were released by the National Heart, Lung, and
Blood Institute’s (NHLBI’s) 2014 Expert Consensus Panel. Guidelines were also recently published by the American Society of Hematology (ASH) [10], although the timing of publication
prevented their inclusion in this study. Together, these two sets of guidelines are used by
experts to inform the standard of care [10,11]. Guidelines help improve quality of care by
improving clinical decision-making and expediting new scientific and therapeutic advances.
The NHLBI and ASH SCD guidelines emphasize that SCD comprehensive care and preventive
care are delivered in the non-acute, ambulatory setting.
The guidelines were intended to improve care by supporting physicians in treating patients
with SCD. Yet, despite efforts to disseminate guidelines, many physicians are unaware of their
existence [13]; and, when they are aware, they often do not show adherence [14]. There are
patient-, provider-, and system-level barriers to explain this implementation gap (i.e., the gap
between what is known to be effective in research and what is implemented in practice). For
example, barriers exist when implementing guidelines in a standard, nonspecialist primary
care setting because insurance companies commonly do not reimburse for certain types of difficult and time-consuming activities outlined in the guidelines. Moreover, many providers do
not have access to SCD specialists for support. This results in individuals with SCD receiving
sub-optimal care, despite being seen by a physician. Even when physicians knowledgeable of
the guidelines do exist in a given geographical area, a significant proportion of individuals
with SCD do not have access to these specialists (e.g., due to transportation, insurance concerns, and other barriers) or have inconsistent clinic attendance (and therefore do not receive
the benefits of the care). Inconsistent attendance at specialty clinics is likely a multifactorial
problem and an active area of empirical inquiry [15]. Regardless of the cause, unaffiliation
from SCD-specific care often results in preventable acute care encounters, including the ED or
hospitalization [16]. It is very hard to implement evidence-based interventions in these contexts, and therefore patients end up with unmet needs and poorer clinical outcomes.
From a research perspective, patient overreliance on the emergent or acute care system
(versus a comprehensive care approach) poses significant concerns for how we understand
and treat SCD. Since the population of patients who are unaffiliated from the SCD preventative care system are not well defined, we do not know the extent to which those individuals
who do not receive care or only receive acute care resemble those who regularly receive comprehensive care by an expert physician. Existing SCD studies tend to draw from the populations of individuals with SCD that the researchers could access, which are typically not those
unaffiliated from the system. This means that we do not know the extent that existing knowledge on SCD applies to those who are unaffiliated from care. Existing studies may be biased by
the availability and accessibility of SCD patients willing to participate in the research. While
the population of interest is “all individuals with SCD”, samples used are “patients with SCD
involved in comprehensive care”.
There is no current definition of “unaffiliation” in the SCD field nor a uniform definition as
there is in other complex chronic disease fields like HIV, mental health, diabetes, or juvenile
rheumatoid arthritis. In other fields, patients who “disengaged,” “dropped out,” “abandoned
care,” or were “out of care” or “lost to follow-up” are defined with both the type of care missed
and a time frame without appointments, ranging from 6 months [17,18] to 1 year [19,20] to 2
years [21–23]. The lack of uniform definitions in SCD creates a problem for researchers: interventionists cannot target a group of people without a clear definition of whom they were
targeting.
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Sickle cell disease implementation consortium
In 2016, the National Heart, Lung, and Blood Institute funded the Sickle Cell Disease Implementation Consortium (SCDIC) to address implementation barriers to the provision of highquality care for SCD [24]. This funding represents a major opportunity for system-level change
in relation to SCD. It is the first research program to use implementation science (defined as
“the scientific study of methods to promote the systematic uptake of research findings and
other evidence-based practices into routine practice, and, hence, to improve the quality and
effectiveness of health services” [25]) to identify and address barriers to care for SCD. SCDIC
is an eight-site consortium of academic medical centers with specialized sickle cell treatment
centers across the United States, comprising both sickle cell experts and implementation scientists collaborating to improve the quality of sickle cell care. An initial goal of SCDIC was to
ensure that individuals with SCD receive guideline-based SCD care. However, it became difficult to assess what constituted an SCD-specialist, which slowed the movement in the consortium’s ability to identify and connect unaffiliated patients to care. Thus, a primary aim
(among others described elsewhere [24]) of the consortium is to understand why affected individuals are not affiliated with SCD clinics or expert providers and to reconnect them with
high-quality care.
At the start of the project, the SCDIC Unaffiliated Patients Working Group had proposed a
working definition: “a person with SCD who has not seen an adult SCD specialist for ambulatory clinic in 2 years.” This definition was regarded as searchable in administrative databases,
and 2 years without an outpatient visit would mean that guideline-based annual screenings
would certainly have been missed. However, the working group soon realized through conversations with experts and patient stakeholders that there was substantial disagreement with different aspects of this definition, specifically regarding the time since the last outpatient visit
and the type of provider required. Variations in perspectives were the result of different experiences, roles, and familiarity with different patient populations (e.g., rural settings where access
to a physician with expertise in SCD is unavailable versus urban settings where unaffiliation
may be for other reasons). There was also disagreement over what constitutes an “SCD specialist” provider. For example, key stakeholders and experts discussed whether a primary care
physician could be a specialist (or only hematologists), as well as the types of experiences,
training, and knowledge required to be a specialist. Unifying the different perspectives across
experts with diverse experiences with SCD presented a challenge with the nuances of the definition. This was the stimulus for the current consensus building process.

The present study
Because the study of “unaffiliation” in the context of SCD is relatively new, a clear definition
was needed to shape the field in a meaningful way. This study was conducted to use a systematic consensus-building process to obtain the definition of unaffiliation. We wanted to ensure
that all expert perspectives were taken into consideration so that the foundational definitions
were not biased by a few individuals on the project. We aimed to capitalize on the breadth of
knowledge and experiences from both researchers on the project and clinical practitioners,
guideline (best practices) developers, and funders, along with experts with representation from
professionals in diverse settings and patient populations. The primary objective of this study
was to conduct a Delphi consensus-building process to decide on a working definition of “an
unaffiliated patient with SCD.” We specifically sought agreement in the following overarching
domains: (a) the type of providers patients need to see to be considered affiliated; (b) the
requirements to be considered a SCD specialist; and (c) the length of time out of care to be
considered unaffiliated.
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Methods
As part of the SCDIC, we conducted a Delphi process with people with professional expertise
in SCD (i.e., researchers, practitioners, funders) to obtain consensus on terms related to “unaffiliation” from SCD. Details of our purposeful sampling appear below. The Delphi technique,
primarily developed by Dalkey and Helmer [26] at the Rand Corporation in the 1950s, is a
widely used and validated method of obtaining consensus about real-world knowledge solicited from experts within certain topic areas [27]. It involves multiple rounds of questioning via
questionnaires to obtain collective opinions of experts until a consensus is reached. In this
study, we used 80% agreement as evidence of consensus. Three rounds of surveys were
planned and sent out electronically. Reminders were sent to increase participation about once
a week (a total of approximately three reminders each round). We did not collect names or
affiliations with surveys; however, information about the work setting and other identifiable
factors (see below) were collected, rendering the survey confidential but not completely
anonymous.
The Delphi survey was developed collaboratively by the SCDIC workgroup of SCD experts
and implementation scientists. We used the following working definition as a stimulus for the
development of the survey items: “An unaffiliated patient is a person with SCD who has not
seen an adult SCD specialist for ambulatory clinic in 2 years.” We obtained input from a group
of eight adults living with SCD (stakeholders in SCDIC) on the survey and response items; in
particular, this group provided input on the duration of time since last visit, with 12 months
(instead of the 2 years in the original definition) selected as the benchmark to correspond to
annual check-ups. This group was used to ensure that the patient perspectives were included
in the study design. The format of these discussions was open-ended and collaborative in
nature. The final survey was approved by the broader SCDIC leadership, including NHLBI
representatives not participating in the study.
In round 1, a set of 16 items (including 4 demographic questions) were included that asked
participants to rate agreement on a set of items related to definitional terms related to “unaffiliation” and SCD experts. Most items were scored as a “yes/no” or multiple choice format.
Open-ended questions were also included to elicit ideas related to unaffiliation that may have
been missed. In rounds 2 and 3, items that did not reach consensus in the previous round were
resent to participants. Round 2 consisted of 14 questions (including 4 demographic questions);
round 3 consisted of 11 questions (including 4 demographic questions). Results of the previous
round were also provided for each item. This is standard in a Delphi technique to help move
participants toward consensus. Additional items were added to each round that reflected contributions from the open-ended questions.
At the end of the Delphi, we conducted a teleconference debriefing focus group where all
participants were invited to participate. During this call, we shared results and facilitated targeted discussions of the implications of the findings. This helped us obtain clarity over some
items and deepen our understanding of the quantitative results.
This study was approved through the Institutional Review Board of the University of Illinois, Chicago. Surveys were sent out via email directly from the research team to the invited
participant. Informed consent was provided; consenting participants clicked a link that
directed them to a confidential survey to begin.

Participants
Participants of this study were specifically selected based on their range of knowledge and
experience working with SCD. We used a purposeful sample of researchers, practitioners, and
NHLBI scientists. We intended to sample from the following non–mutually exclusive areas: at
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least two of the original authors of the NHLBI 2014 guidelines, two representatives from
NHLBI, three members of the workgroup within SCDIC focused on unaffiliation (these participants were not part of the planning or analysis of this study), at least 10 clinicians who work
with SCD patients, and at least eight investigators from the SCDIC consortium, plus additional
investigators recognized in the SCD field who fit a need from the other criteria for our purposeful sample (e.g., working with rural populations, primary-care specialists who specialize in
SCD). Our final sample appears in the next section. Additionally, we sought representation
from the following domains: role (researcher, policy level, practitioner, developer of guidelines), primary setting (urban, rural), population expertise (adult/pediatric), work setting
(SCD center, ED, primary care, non–SCD center hematology), involvement with SCDIC
(involved as an investigator or core team member, not involved). Recruitment of participants
occurred via direct email to potential participants.

Results
Twenty-eight experts were invited to participate in the Delphi process through this selection
strategy. All participants were MDs, except for one nurse/researcher and one nurse practitioner. Characteristics of respondents appear in Table 1.

What is an unaffiliated patient?
Results from the three rounds of the Delphi process appear in Table 2. Our first line of inquiry
focused on the type of provider a patient must see to be considered affiliated. By round 2,
Table 1. Characteristics of participants.
Round 1
(n = 21)

Round 21
(n = 16)

Round 3
(n = 20)

Researcher (general)

5%

6%

6%

Researcher (focus sickle cell disease)

36%

34%

40%

NIH leadership

0%

3%

0%

Guidelines developer

19%

19%

18%

Provider

40%

38%

36%

Urban

75%

69%

84%

Rural

5%

6%

0%

Suburban

10%

19%

11%

Other

10%

6%

6%

Adults

50%

44%

56%

Children

25%

19%

17%

Both

25%

38%

28%

Less than 50%

45%

44%

32%

Greater than 50%

55%

56%

68%

Primary Role2

Work Setting

Target Population (Patients)

Proportion of Time Working with SCD

1

In round 2, there were 19 responses with 3 with complete nonresponse. In Round 3, there were 20 responses with 1

complete nonresponse.
2

Respondents were asked to indicate their primary role if they had dual roles. Only one response option could be
selected.
https://doi.org/10.1371/journal.pone.0272204.t001
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Table 2. Results of the Delphi survey items related to defining unaffiliation.
Question: For a person with sickle cell disease to be affiliated, do they need to see a sickle cell specialist?
Round 1

Round 2

Round 3

Yes

62%

88%

N/A

No

35%

13%

N/A

Unsure

5%

0%

N/A

Question: What type of provider must a person with sickle cell disease see to be affiliated?
Round 1

Round 2

Round 3

Sickle Cell Disease Specialist

65%

88%

N/A

Primary Care Physician

10%

0%

N/A

Advanced Provider (AP) in a Hematology Office

5%

0%

N/A

AP in an PCP office

20%

13%

Question: A person with sickle cell disease should be considered unaffiliated if the person has not been seen by a
provider outside the emergency department or urgent care setting in:
Round 1

Round 2

Round 3

More than 6 months

0%

N/A

N/A

More than a year

76%

75%

89%

More than 2 years

10%

25%

11%

More than 3 years

5%

0%

0%

Unimportant

5%

0%

0%

Other

5%

N/A

N/A

Question: When do you consider a patient lost to follow-up (e.g., no care follow-up, missed appointments)?
Round 1

Round 2

Round 3

More than 6 months

5%

N/A

N/A

More than a year

52%

63%

53%

More than 2 years

38%

31%

47%

More than 3 years

5%

6%

0%

Unimportant

0%

0%

0%

Other

0%

N/A

N/A

https://doi.org/10.1371/journal.pone.0272204.t002

consensus was reached that for a patient to be affiliated, a person with SCD must be seen by an
SCD specialist (62% round 1; 88% in round 2). We define what it means to be an SCD specialist in the next section.
The second line of inquiry related to the definition of unaffiliation was the duration of time
out of care before a patient is considered unaffiliated. In round 3, experts reached consensus
that a person with SCD is considered unaffiliated if they were not seen by any SCD specialist
in more than a year. In further conversations with the SCDIC and experts in the field, however,
nuances related to this issue continued to be deliberated. Specifically, experts discussed the
issue of unaffiliation due to being lost to follow-up and the amount of time needed between
appointments before an individual is considered unaffiliated. While it was clear that a lack of
contact with a provider (out of care) in a year led to the determination of “unaffiliation”, there
was less agreement regarding time between appointments and the designation of unaffiliation.
Some experts felt that a year between appointments was sufficient to be considered “lost to follow-up” (and therefore unaffiliated); others felt that the time between appointments should be
two years before determining “lost to follow-up” (and therefore unaffiliated). Consensus on
the amount of time between appointments before a person is considered unaffiliated as a result
of being lost to follow-up was not reached.
Last, we probed whether there are characteristics of patients that should be considered in
defining unaffiliation, beyond the type of provider seen and duration of time since last
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Table 3. Additional factors that should be considered in the definition of an unaffiliated patient.
Question: Should each of the following factors be considered in the definition of an unaffiliated person with sickle cell
disease? (yes/no; % yes reported)
Routine use of emergency department services

63%

Not getting recommended routine sickle cell disease screenings

89%

Proportion of use of inpatient to outpatient care

47%

Location and distance from a sickle cell disease specialist

47%

A joint model of multiple providers (e.g., sickle cell disease specialist and hematology/oncology trained
provider in the interim)

58%

Patient knowledge of disease and necessary care

26%

https://doi.org/10.1371/journal.pone.0272204.t003

appointment. In rounds 1 and 2, we asked if there were other factors beyond those on the survey that should be considered when defining an unaffiliated SCD patient. Responses to these
questions were included in the round 3 survey (see Table 3). The only item that reached consensus was not getting recommended routine SCD screenings. Further, there was consensus in
round 1 that there are no exclusions when considering unaffiliation (81%), including healthy
individuals who rarely or never get pain or need hospitalization (0% responded that this population can be excluded), adolescents who aged out of pediatrics and have been lost to follow-up
(5% responded that this population can be excluded), patients dismissed from care for nonadherence (5% responded that this population can be excluded), and patients dismissed for
another reason (10% responded that this population can be excluded).

What is an SCD specialist?
To help understand the type of care a patient must receive to be considered affiliated, we asked
participants, “What types of knowledge and experience must a provider have in order to be considered a SCD expert?” Results appear in Table 4. To be considered a sickle cell specialist, consensus was reached on the following criteria: knowledge of the 2014 NIH Guidelines,
“Evidence-Based Management of SCD”; experience working with SCD patients; has been
mentored by an SCD specialist; regularly attends SCD conferences, trained in pain management; trained on SCD emergencies; trained on hydroxyurea management; trained on transfusions; trained on screening for organ damage in SCD; and awareness of psychosocial and
cognitive issues in SCD. There was agreement that continuing medical education in SCD specific issues should be obtained at least every 2 years.
One area of discrepancy and follow-up discussion among the SCDIC members was whether
an Advanced Primary Care provider (APC) could be considered a specialist. Based on the
results of the first two rounds (including open-ended questions), we added a question in
round 3 that asked, “If a patient sees an APC, is the patient considered affiliated with SCD
care?” This question did not reach consensus, with only 47% of respondents answering affirmatively. Because we did not reach consensus, APCs are not included as specialists in our definition. Proponents of including APCs as specialists argued the benefits of having a specially
SCD-trained APCs in PCP offices; these APCs could act as affiliates to a SCD network of providers (in contrast to a PCP without the specialized training).

Discussion
The purpose of the current study was to obtain consensus using a Delphi process on the definition of “unaffiliation” from SCD care. Consensus was achieved for the following definitions of
“unaffiliation from SCD care” and “sickle cell specialist”:
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Table 4. Characteristics of an SCD specialist.
Question: What type of knowledge/training and experience must a provider have to be considered a sickle cell
specialist? (yes/no)1
Round 1 Round
2

Round
3

Knowledge of the 2014 NIH Guidelines, "Evidence-Based Management of SCD"

90%

N/A

N/A

Experience working with sickle cell disease

95%

N/A

N/A

Experience on sickle cell disease research studies

24%

31%

26%

Mentored by a sickle cell disease specialist

52%

93%

N/A

General Fellowship experience sufficient

20%

27%

26%

Fellowship training in sickle cell disease

19%

25%

11%

General fellowship training in hematology-oncology

35%

38%

47%

Attend sickle cell disease conferences regularly

52%

100%

N/A

Training in pain management

62%

81%

N/A

Training on sickle cell emergencies

N/A

100%

N/A

Primary care-based sickle cell disease experience (i.e., seen more than 10 patients in
the primary care setting with sickle cell disease)

50%

75%

74%
N/A

Training on hydroxyurea management

85%

N/A

Training on transfusion decisions

90%

N/A

N/A

Training on screening for organ damage in sickle cell

80%

N/A

N/A

Awareness of psychosocial and cognitive issues in sickle cell

86%

N/A

N/A

Question: How often should a sickle cell specialist be required to obtain Continuing Medical Education credit?
Round
1

Round 2

At least annually

33%

44%

At least every 2 years

48%

56%

84%

Not Necessary

14%

0%

N/A

Other

5%

N/A

N/A

1

Round
3
16%

In Round 1 was asked in 2 questions: What type of knowledge/training must a provider have to be considered a

SCD specialist? And What type of experience must a provider have to be considered a SCD specialist?
https://doi.org/10.1371/journal.pone.0272204.t004

“An individual with SCD considered unaffiliated is someone who has not been seen by a
sickle cell specialist in at least a year.
A sickle cell specialist is someone with knowledge and experience in SCD. Having “knowledge”
means: being knowledgeable of the 2014 NIH Guidelines, “Evidence-Based Management of
SCD”, trained in hydroxyurea management and transfusions, trained on screening for organ
damage in SCD, trained in pain management and on SCD emergencies, and is aware of psychosocial and cognitive issues in SCD. Experiences that are expected of a SCD specialist include experience working with SCD patients, mentored by a SCD specialist, regular attendance at SCD
conferences, and obtains continuing medical education on SCD every 2 years.” The type of conference or continuing medical education was not specified in this survey.
Obtaining consensus on these foundational terms is an important first step to advance the
research and practice of quality care in SCD. Unaffiliated patients are likely a heterogeneous
group of individuals that will require different strategies for affiliation and retention. Having a
shared understanding of what it means to be unaffiliated will allow researchers to conduct
studies that can optimize connecting diverse individuals with SCD to specialized care. This
definition will allow researchers to quantify study endpoints and will also be used to support
policies related to SCD care and the allocation of resources to connect patients to high-quality
care.

PLOS ONE | https://doi.org/10.1371/journal.pone.0272204 November 11, 2022

9 / 14

PLOS ONE

What is an unaffiliated patient?

Despite the contribution of this study to research and policy, we share a few cautions when
applying this study to the realm of practice without further investigation. First, we recognize
that the definition of SCD specialist has several areas that could be improved and clarified.
One update is that the NIH 2014 guidelines were the only national guidelines in existence at
the time this study was conducted. During this study, additional evidence-based guidelines
emerged for the treatment of SCD sponsored by the ASH guidelines in 2019–2020. Further,
the type of conference attendance required (including SCD-specific meetings) and the optimal
continuing medical education necessary is needed.
Second, the purpose of this study was to advance SCD research, and we caution against
strict adherence to the definitions in this study in clinical settings, particularly where “specialists” do not exist. We do not encourage current nonspecialist providers to remove individuals
with SCD from their practices, unless successfully transferring to a specialist care provider. An
alternative would be to acknowledge limitations of knowledge and either link to a SCD specialist or draw upon SCD treatment materials available through ASH. Existing models for linkages
include: 1)“hub-and-spoke” models whereby SCD expertise is extended to areas without existing SCD specialists through the collaboration of nonspecialist PCPs or advance practice providers; 2) telemedicine in collaboration with local providers; or 3) intermittent care provided
by specialists who travel to rural areas to support the care provided by primary care physicians
between specialty visits [28,29]. In these models, patients may not be able to see specialists face
to face but may be able to affiliate with them to help enhance care.
Similarly, nonspecialist providers might communicate indirectly with SCD specialists for
affected patients, effectively imparting specialist-recommended care. Existing models include:
(1) Community nonspecialist hematologists/oncologists with substantial numbers of benign
hematology patients maintaining regular contact with academic SCD specialists on a regular
basis (even if the patients are not seen at the academic medical center SCD clinic), along with
attending annual ASH meetings, and using ASH resources; (2) Care provided by nonspecialists participating in successful SCD ECHO programs;(3) Routine care by nonspecialists with
have their care guided by an SCD specialist at a local outreach clinic (e.g., Augusta University
program); 4) Mentoring models whereby SCD specialists use telehealth or telemedicine to provide support to nonspecialists and direct patient-provider assistance; or 5) Co-management
between pediatric primary health providers, pediatric specialty care, and future adult providers
to support transitions for pediatric subpopulations [30]. This is an area of future work to better
understand the effectiveness of various options for network providers.
Another practical consideration from this study is the question of how patients will know if
their provider is an SCD specialist. We anticipate that patients are often unaware of the types
of training and continuing education that their provider has, nor do they know their experiences working with SCD or knowledge of different SCD care strategies. It is our experience
that patients are aware of educational background from brief overviews on websites or degrees
handing on walls, but do not inquire deeply about the training experiences of the provider.
This creates a loophole where we classify providers into specialist and non-specialist categories;
but, are unable to connect patients to these providers. One potential solution is the establishment of a network, credential, or repository of sickle cell centers and specialist providers that
can be used by patients to identify providers who can best meet their needs. This type of system
should be developed through collaboration with SCD researchers, providers, implementation
scientists, and the patient perspective to ensure a systematic approach where all potential risks
and implications are considered. An example of potential risk is the situation of third-party
payors limiting options for patients with SCD (based on these results); this may restrict all care
for certain individuals who only have access to nonspecialists in their geographical region.
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Practical changes deriving from the definition should be accompanied by system-level changes
that support access to quality care and avoid any new barriers to accessibility.
The impact of this work is to help lay a foundation of research that helps unaffiliated
patients connect to care. We recognize however that affiliation is different from engagement.
Engagement may be a more relevant construct for certain applications, particularly those that
are patient-facing. A patient, for example, may consider themselves affiliated with care because
they identify with a clinic, and know whom to call for an emergency or for particular needs
(e.g., if they need to see a sickle cell specialist for preparation for surgery). Yet, they may not
have attended clinic in a while based on perceived need. In this case, they may be affiliated but
not engaged with care. Differentiating the overlapping constructs of affiliation and engagement, and how they translate to clinical outcomes separately and jointly, is an important area
for future work.
While this study reached consensus among professionals with expertise in SCD, we recognize a limitation is that patient perspectives were not included. Patients with SCD are also
often experts in their own disease with lived experiences. Obtaining alignment between the
patient perspective and professional perspective will be important to build cohesion and
improve care. As a follow-up to this study, the research team will be conducting a nationwide
quantitative survey where we probe specific questions related to affiliation, agreement with
professional opinion, and patients’ own self-identification of being affiliated (and engaged) or
not. A particular area for further exploration will be on the duration of time since last appointment in relation to unaffiliation.
Another limitation of this study arises from the measurement of the criteria for SCD specialists. In this survey, we asked participants, “What type of knowledge/training and experience
must a provider have to be considered a SCD specialist?” and provided a set of criteria with
yes/no response options. The benefit of this approach was that it was easy for participants to
complete in a rapid way and it helped us isolate which criteria were deemed most important
among a pool of potential criteria. The limitation is that we are unable to determine whether
all the criteria need to be met, or some of the criteria are sufficient (and which ones are necessary). To address this limitation, we facilitated multiple discussions with experts (including a
focus group among Delphi participants) and feel confident that all criteria must be met to be
considered a specialist. It was noted that most responders did check all of the boxes to indicate
“all criteria” must be met but the question was not posed in this way. Simultaneously, we
acknowledge that there may be variability in the types and quality of knowledge and experience, and this definition should not be interpreted as a hard rule. For example, if a provider
meets all criteria except mentorship, then he or she may potentially still be considered a specialist provider. Similarly, although APCs were not deemed experts in this study, we hypothesize that an APC who meets all other criteria or who works closely with an MD SCD specialist
in a network of care may be considered a specialist in another follow-up study. An additional
limitation of our measurement was that we did not include “hematologist” as a potential category for “specialist”. This was by design because we were investigating providers that could be
specialists beyond trained hematologists. We recognize that not all hematologists are specialists in SCD, however, and this is an area worthy of future inquiry. Distilling core versus more
peripheral criteria is an important area of future work, particularly if a credential or provider
network is developed.

Conclusion
Although SCD is a rare disease, comprehensive care by providers who understand the uniqueness of the disease is needed. This poses a challenge in implementation because many
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providers simply do not have the requisite expertise to provide adequate care, leaving many
patients at risk for negative health outcomes. This study advanced the field by establishing
foundational terms that will support advanced research and practice in the care of SCD.
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